Scott Hensley

Scott Hensley appears in the following:

WATCH: Harvard-NPR panel on the fight to tame COVID

Friday, November 12, 2021

Watch an expert panel discuss the latest developments and challenges in the COVID-19 pandemic livestreamed at noon ET on Friday.

Comment

Moderna says new data supports its COVID vaccine for kids 6 to 11

Monday, October 25, 2021

Moderna says a study in kids 6 to 11 found two doses of the company's COVID-19 vaccine given 28 days apart produced a strong antibody response.

Comment

Pfizer-BioNTech COVID vaccine appears more than 90% effective in kids 5 to 11

Friday, October 22, 2021

The companies studied a 10 microgram vaccine dose in children 5 to 11, a third of the dose used for adults, to minimize side effects and because it still prompts a strong immune response.

Comment

CDC backs the rollout of COVID vaccine boosters from Moderna and J&J

Thursday, October 21, 2021

CDC Director Rochelle Walensky also endorsed a mix-and-match approach to boosters that would be flexible for patients and health care providers.

Comment

The FDA authorizes Moderna and J&J COVID vaccine boosters

Wednesday, October 20, 2021

The Food and Drug Administration also gave an OK to boosters that differ from the vaccine originally used to immunize people against COVID-19. A mix-and-match approach could ease the booster rollout.

Comment

An FDA panel of experts backs J&J COVID vaccine booster

Friday, October 15, 2021

A panel of experts voted to recommend that the Food and Drug Administration authorize a booster dose of the Johnson & Johnson COVID vaccine at least two months after the first shot.

Comment

Experts recommend that FDA should authorize Moderna COVID vaccine booster

Thursday, October 14, 2021

The recommendation applies to people 65 years and older, those 18 to 64 who are at high risk of severe COVID and those whose work or institutional exposure puts them at high COVID risk.

Comment

FDA analysis of J&J COVID vaccine booster sets the stage for public hearing

Wednesday, October 13, 2021

Johnson & Johnson has asked the Food and Drug Administration to authorize a booster for people 18 and older six months after initial immunization, with an option to vaccinate after two months.

Comment

Moderna and J&J say their data supports COVID vaccine boosters

Tuesday, October 12, 2021

The Food and Drug Administration released briefing documents Tuesday on booster shots for the Moderna and Johnson & Johnson COVID vaccines ahead of a two-day advisory meeting that starts Thursday.

Comment

The FDA OKs Pfizer-BioNTech Booster For People 65+ Or At High Risk For Severe COVID

Wednesday, September 22, 2021

A third shot of the vaccine can be given at least six months after the two-dose regimen, according to the authorization. A booster rollout could begin this week.

Comment

An FDA Panel Says Only High-Risk Americans And Those 65+ Should Get COVID Boosters

Friday, September 17, 2021

Advisers to the Food and Drug Administration supported boosters of the Pfizer-BioNTech COVID-19 vaccine for a smaller group of people after they voted against recommending it for anyone 16 and older.

Comment

A Pfizer Analysis Makes The Case For A COVID Vaccine Booster

Wednesday, September 15, 2021

Pfizer says data supports its request for Food and Drug Administration approval of a third dose of the COVID-19 vaccine about six months after the second dose in people 16 years and older.

Comment

Pfizer-BioNTech's COVID Vaccine Gets Full Approval From The FDA

Monday, August 23, 2021

The approval replaces the emergency use authorizations granted last December and could make it easier for employers, the military and universities to mandate vaccination.

Comment

The FDA Has Approved A New Alzheimer's Drug — Here's Why That's Controversial

Monday, June 07, 2021

This is the first new drug approved for Alzheimer's disease since 2003. It's the first to show significant progress against the sticky brain plaques that are the hallmark of Alzheimer's disease.

Comment

Latest AstraZeneca Report Supports Effectiveness Of COVID Vaccine

Wednesday, March 24, 2021

Updated study results say the vaccine is 76% effective against symptomatic COVID-19 and 100% effective against severe disease. Independent monitors had been concerned about a previous report.

Comment

FDA Authorizes Johnson & Johnson's One-Shot COVID-19 Vaccine

Saturday, February 27, 2021

The Food and Drug Administration gave Johnson & Johnson's vaccine the green light for emergency use Saturday, a day after a panel of advisers to the agency endorsed it in a unanimous vote.

Comment

Panel Recommends FDA Authorize Johnson & Johnson Vaccine For Emergency Use

Friday, February 26, 2021

The Food and Drug Administration typically follows the advice of its expert advisers. A quick agency decision on the Johnson & Johnson vaccine is expected given the state of the pandemic.

Comment

FDA Analysis Of Johnson & Johnson COVID-19 Vaccine Finds It Safe, Effective

Wednesday, February 24, 2021

The Food and Drug Administration released an analysis of Johnson & Johnson's COVID-19 vaccine Wednesday morning that appears to support its authorization for emergency use.

Comment

Johnson & Johnson Vaccine Is 66% Effective In Preventing Moderate To Severe COVID-19

Friday, January 29, 2021

The vaccine did better at preventing disease in the U.S. – 72% — and less well in South Africa – 57% efficacy. The efficacy seen in Latin America was 66%.

Comment

Novavax COVID-19 Vaccine Effective, But Less So Against Variant In South Africa

Thursday, January 28, 2021

Novavax says its COVID-19 vaccine is 89% effective at preventing illness, according to an interim analysis of a U.K. study. But the vaccine wasn't as effective against some viral variants.

Comment